Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02686268 · ClinicalTrials.gov registry record
Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 128
- Enrollment target
NCT02686268: Completed study, sponsored by Washington University School of Medicine.
NCT02686268 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 128 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02686268 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 128 participants
- Enrollment target
Study Summary
This research study is being performed to better understand a specific form of Amyotrophic Lateral Sclerosis (ALS) caused by a mutation (or abnormality) of the C9ORF72 gene. This mutation is the most common genetic cause of ALS, and is present in 40% of ALS patients with a family history of ALS and 5-10% of ALS patients without a family history of ALS.
Primary Outcome
The primary outcome measures will be the collection of clinical data (ALSFRS, ALS-CBS and SVC) to determine rates of disease progression and collection of biomarkers samples (blood, CSF) to be correlated with the clinical measures.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2015-02 |
| Est. Completion | 2018-10-02 |
What the finished NCT02686268 record still lists
NCT02686268 is an observational study that tracks outcomes without assigning an intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02686268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02686268 about?
NCT02686268 is a clinical study titled "Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS". This research study is being performed to better understand a specific form of Amyotrophic Lateral Sclerosis (ALS) caused by a mutation (or abnormality) of the C9ORF72 gene. This mutation is the most common genetic cause of ALS, and is present in 40% of ALS patients with a family history of ALS and ...
What is the current status of trial NCT02686268?
This trial is currently completed. The enrollment target is 128 participants. The study started on 2015-02. Estimated completion is 2018-10-02.
Who is sponsoring clinical trial NCT02686268?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia